Marker Therapeutics, Inc.

Category: Press Releases

Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma

Marker Therapeutics today announced that updated clinical data from an investigator-sponsored Phase 1/2 trial led by Baylor College of Medicine were selected for oral presentation during a plenary session at the upcoming American Association for Cancer Research’s (AACR) Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy conference.

Read More

Marker Therapeutics to Present at Two Upcoming Investor Conferences

Marker Therapeutics will present at and participate in two upcoming investor conferences.

Read More


Marker Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference

President and Chief Executive Officer, Peter L. Hoang, to present at the 2019 Bank of America Merrill Lynch Health Care Conference.

Read More

Marker Therapeutics Provides Business and Clinical Update

Company to host business update call and webcast today at 5:00 p.m. EDT

Read More

Marker Therapeutics to Host Business Update Conference Call and Webcast on Thursday, March 28th

Marker Therapeutics announces business update conference call and webcast on Thursday, March 28th.

Read More

Marker Therapeutics Announces Clinical Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019

Marker Therapeutics announces updated data from four clinical trials using the Company’s multi-antigen targeted T cell (MultiTAA) therapies.

Read More

Marker Therapeutics Congratulates Helen E. Heslop, MD, DSc (Hon), on Receiving the ASBMT Lifetime Achievement Award

Marker Therapeutics would like to congratulate Scientific Advisory Board Member, Helen E. Heslop, MD, DSc (Hon), on receiving the ASBMT Lifetime Achievement Award.

Read More

Marker Therapeutics to Present at the CAR-TCR Summit Europe

President and CEO, Peter L. Hoang, and Chief Development Officer, Dr. Juan Vera, will be presenting at the CAR-TCR Summit Europe.

Read More

Marker Therapeutics Announces Change in Corporate Headquarters and Access to New Laboratory Facility

Marker Therapeutics has formally relocated their corporate headquarters from Jacksonville, Florida to Houston, Texas. In addition, the Company has announced that it is now a resident company at Johnson & Johnson Innovation – JLABS (JLABS at TMC).

Read More